Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
PBLA They walked it down with little 100-400 share trades for the past hour.
TENX .19
You're right about that. When it gets those millions share days it definitely moves. PBLA
PBLA .37 with some nice ask slapping. Hit .53 Monday
PBLA .37 nice ask hit
Have more bidders than usual and they are trying to hold it down here. PBLA
PBLA news 17M float. Hit .53 monday and .99 recently
Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
September 29 2022 - 09:00AM
GlobeNewswire Inc.
Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced Regulatory approval for the opening of trial sites in Spain, France and Italy for Panbela’s clinical trial in the first-line treatment of metastatic pancreatic cancer. ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. Detailed information on the trial can be located at https://clinicaltrials.gov/ct2/show/NCT05254171.
With approximately 95 sites planned throughout the United States, Europe, Australia, and South Korea, we are continuing to focus on site initiation and enrollment in order to ultimately deliver a more effective treatment for pancreatic cancer, a deadly disease with few treatment options. Site initiation can now accelerate, and we are pleased with the current momentum of the ASPIRE trial. We expect that a significant number of global sites will be open by year-end with the full complement of sites open by the first quarter 2023. “We’re excited to have these recent approvals as we move forward towards the interim analysis which is expected to be completed in early 2024,” commented Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela.
PBLA .35 Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
September 29 2022 - 09:00AM
GlobeNewswire Inc.
Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced Regulatory approval for the opening of trial sites in Spain, France and Italy for Panbela’s clinical trial in the first-line treatment of metastatic pancreatic cancer. ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. Detailed information on the trial can be located at https://clinicaltrials.gov/ct2/show/NCT05254171.
With approximately 95 sites planned throughout the United States, Europe, Australia, and South Korea, we are continuing to focus on site initiation and enrollment in order to ultimately deliver a more effective treatment for pancreatic cancer, a deadly disease with few treatment options. Site initiation can now accelerate, and we are pleased with the current momentum of the ASPIRE trial. We expect that a significant number of global sites will be open by year-end with the full complement of sites open by the first quarter 2023. “We’re excited to have these recent approvals as we move forward towards the interim analysis which is expected to be completed in early 2024,” commented Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela.
TENX .18 low floater
still holding my shares for the big move
PBLA Panbela Receives Approvals to Open Trial Sites in Spain, France and Italy for ASPIRE Trial Studying Ivospemin (SBP-101) in Combination with Gemcitabine and Nab-Paclitaxel in Patients with Metastatic Pancreatic Ductal Adenocarcinoma
September 29 2022 - 09:00AM
GlobeNewswire Inc.
Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs, today announced Regulatory approval for the opening of trial sites in Spain, France and Italy for Panbela’s clinical trial in the first-line treatment of metastatic pancreatic cancer. ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. Detailed information on the trial can be located at https://clinicaltrials.gov/ct2/show/NCT05254171.
With approximately 95 sites planned throughout the United States, Europe, Australia, and South Korea, we are continuing to focus on site initiation and enrollment in order to ultimately deliver a more effective treatment for pancreatic cancer, a deadly disease with few treatment options. Site initiation can now accelerate, and we are pleased with the current momentum of the ASPIRE trial. We expect that a significant number of global sites will be open by year-end with the full complement of sites open by the first quarter 2023. “We’re excited to have these recent approvals as we move forward towards the interim analysis which is expected to be completed in early 2024,” commented Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela.
oh it's going quick. As soon as it's feasible we're gonna travel. Man I'm sorry for your loss.
lol it's very common for a guy let's say retired to get with a 20 something Filipino... pretty much so she can come to the US. I mean he gets young arm candy, she gets to stay here after they are married for 2 years.
oh niiice. Always wanted to live in Alaska. I haven't been anywhere in Europe yet. Theres a hundred places we want to travel too. We're still young and have time.
Gotta slow it down and enjoy or you'll just pass everything up. Then get old and be like...whaaat the F. I missed a lot
One of the reasons why I want to move to her country. The less you have the happier you are. And the bamboo house she grew up in is still being used.
and no there isn't a 40 year age gap between us. Just a year. haha
oh that was an alert?! No wonder I woke up with a headache
My wife is from the Philippines. She's been in the US since 2018. She worked in Lebanon for a year (1 month locked in a room with no way out), Dubai for 6 years (12 hours a day 6 days a week). Very poor. Extremely hard worker. When she arrive to the US she said everything is fast and people are so much stressed.
TENX .17 grabbed a starter
TENX .17 grabbed some here
TENX bought .171
grabbed a starter
JSPR 500k volume Monday and it hit 1.15. Gotta be a very low float. Was $2 weeks ago
JSPR bought .83
JSPR .85 Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting
Jasper Therapeutics
Mon, September 26, 2022 at 8:00 AM
Pincher on the chart.
JSPR Jasper Therapeutics Announces Positive Clinical Data from Investigator Sponsored Study of JSP191 Conditioning in Fanconi Anemia Patients at IEWP Annual Meeting
Jasper Therapeutics
Mon, September 26, 2022 at 8:00 AM
Pincher chart as well.
exactly. So JSPR had positive clinical data 2 days ago and doesn't market reacted all too much to the good news yet. A quick pop but I think stronger move is close
yup. I used to do pretty well years ago playing them
hahaha yes. I'm a pincher'er
PBLA .37 up. Red to green move. 17M float
nice pincher forming there too. Nice
PBLA bids creeping up
Positive data plus early pincher chart. trades like very low floater. Keeping close eye. Thanks
JSPR joined you and grabbed some
Enjoy
haha. Thanks. Knowing I had the knowledge and have proven it to myself it was difficult to wait like 10 years for the right time. Huge mistakes, life circumstances, then a return. This is better than sitting and watching tv all day huh.
Sorry for OT post mods
you are correct. Been around a while, made huge mistakes, waited several years for it to be the right time and return. Just returned a couple months ago. I did make a few greed mistakes again but cleared that up. Every single stock I bought went up but missed the sell for it to come back for a break even or minimal gain. But all good now.
hahaha nah they wouldn't do that. There's just so little on the ask, it's pretty nuts PBLA
did you see after .36 hit on ask it was dropped to .35 with 5000 share ask. 100 shares bought at .35 and the 5k disappeared